Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study

Experimental Gerontology

Volumn 50, Issue 1, 2013, Pages 114-121

  Marksteiner, Josef ^a   Imarhiagbe, Douglas ^a   Defrancesco, Michaela ^b   Deisenhammer, Eberhard A ^b   Kemmler, Georg ^c   Humpel, Christian ^c  

^a Department of Psychiatry and Psychotherapy A ^*  (Austria)

^b Department of Psychiatry and Psychotherapy Innsbruck   (Austria)

^c Department of Psychiatry and Psychotherapy   (Austria)

Author keywords

Alzheimer; Biomarker; Diagnosis; Mild cognitive impairment; Multiplex ELISA; NT proBNP; Plasma

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA 2 MACROGLOBULIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIBODY; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOPTOSIS INDUCING FACTOR; BETA DEFENSIN 2; BIOLOGICAL MARKER; FIBRINOGEN; FIBRONECTIN; KERATINOCYTE GROWTH FACTOR; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OXIDIZED LIPID ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PROGRAMMED DEATH 1 RECEPTOR; SERUM AMYLOID A; THROMBOMODULIN; THROMBOPOIETIN; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE PLASMINOGEN ACTIVATOR; TNF LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; VERY ELDERLY;

ALZHEIMER; BIOMARKER; DIAGNOSIS; MILD COGNITIVE IMPAIRMENT; MULTIPLEX ELISA; NT-PROBNP; PLASMA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NATRIURETIC PEPTIDE, BRAIN; NEUROPSYCHOLOGICAL TESTS; PATIENT SELECTION; PEPTIDE FRAGMENTS; PILOT PROJECTS; ROC CURVE;

EID: 84890822406     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2013.12.001     Document Type: Article

References (52)

1. Bayes-Genis A. Plasma NT-proBNP: a new biomarker for diagnosis and monitoring of congestive heart failure (CHF). Timely Top. Med. Cardiovasc. Dis. 2006, 10:E10.
2. Bionda C., Bergerot C., Ardail D., Rodriguez-Lafrasse C., Rousson R. Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann. Clin. Lab. Sci. 2006, 36:299-306.
3. Blasko I., Lederer W., Oberbauer H., Walch T., Kemmler G., Hinterhuber H., Marksteiner J., Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 2006, 21:9-15.
4. Blennow K. CSF biomarkers for Alzheimer's disease: use in erarly diagnosis and evaluation of drug treatment. Expert. Rev. Mol. Diagn. 2005, 5:661-672.
5. Borroni B., Volpi R., Martini G., Del Bono R., Archetti S., Colciaghi F., Akkawi N.M., Di Luca M., Romanelli G., Caimi L., Padovani A. Peripheral blood abnormalities in Alzheimer disease: evidence for early endothelial dysfunction. Alzheimer Dis. Assoc. Disord. 2002, 16:150-155.
6. Borroni B., Di Luca M., Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?. Eur. J. Pharmacol. 2006, 545:73-80.
7. Buerger K., Uspenskaya O., Hartmann O., Hansson O., Minthon L., Blennow K., Moeller H.J., Teipel S.J., Ernst A., Bergmann A., Hampel H. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J. Clin. Psychiatry 2011, 72:556-563.
8. Cedazo-Minguez A., Winblad B. Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exp. Gerontol. 2009, 45:5-14.
9. Dadu R.T., Fornage M., Virani S.S., Nambi V., Hoogeveen R.C., Boerwinkle E., Alonso A., Gottesman R.F., Mosley T.H., Ballantyne C.M. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke 2013, 44:1803-1808.
10. Daniels L.B., Laughlin G.A., Kritz-Silverstein D., Clopton P., Chen W.C., Maisel A.S., Barrett-Connor E. Elevated natriuretic peptide levels and cognitive function in community-dwelling older adults. Am. J. Med. 2011, 124:670-677.
11. De la Torre J.C. Alzheimer's disease as a vascular disorder. Stroke 2002, 33:1152-1162.
12. Desai A.K., Grossberg G.T. Diagnosis and treatment of Alzheimer's disease. Neurology 2005, 64:S34-S39.
13. Erikssen G., Liestol K., Bjornholt J.V., Stormorken H., Thaulow E., Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur. Heart J. 2000, 21:1614-1620.
14. Ewers M., Mielke M.M., Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp. Gerontol. 2010, 45:75-79.
15. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
16. Fradinger E.A., Bitan G. En route to early diagnosis of Alzheimer's disease - are we there yet?. Trends Biotechnol. 2005, 23:531-533.
17. Frey H.J., Mattila K.M., Korolainen M.A., Pirttilä T. Problems associated with biological markers of Alzheimer's disease. Neurochem. Res. 2005, 30:1501-1510.
18. Ghidoni R., Benussi L., Glionna M., Franzoni M., Geroldi D., Emanuele E., Binetti G. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J. Neural Transm. 2008, 115:1047-1050.
19. Hampel H., Blennow K., Shaw L.M., Hoessler Y.C., Zetterberg H., Trojanowski J.Q. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 2010, 45:30-40.
20. Hampel H., Frank R., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9:560-574.
21. Hu W.T., Holtzman D.M., Fagan A.M., Shaw L.M., Perrin R., Arnold S.E., Grossman M., Xiong C., Craig-Schapiro R., Clark C.M., Pickering E., Kuhn M., Chen Y., Van Deerlin V.M., McCluskey L., Elman L., Karlawish J., Chen-Plotkin A., Hurtig H.I., Siderowf A., Swenson F., Lee V.M., Morris J.C., Trojanowski J.Q., Soares H. Alzheimer's disease neuroimaging initiative. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012, 79:897-905.
22. Humpel C. Identifying and validating biomarkers for diagnosing Alzheimer's disease. Trends Biotechnol. 2010, 29:26-32.
23. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Review. Exp. Gerontol. 2011, 46:225-232.
24. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 2004, 5:347-360.
25. Kondziella D., Göthlin M., Fu M., Zetterberg H., Wallin A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. Neureport 2009, 20:825-827.
26. Kubo T., Sato T., Noguchi T., Kitaoka H., Yamasaki F., Kamimura N., Shimodera S., Iiyama T., Kumagai N., Kakinuma Y., Diedrich A., Jordan J., Robertson D., Doi Y.L. Influences of donepezil on cardiovascular system-possible therapeutic benefits for heart failure-donepezil cardiac test registry (DOCTER) study. J. Cardiovasc. Pharmacol. 2012, 60:310-314.
27. Kudo T., Imaizumu K., Tanimukai H., Katayama T., Sato N., Nakamura Y., Tanaka T., Kashiwagi Y., Jinno Y., Tohyama M., Takeda M. Are cerebrovascular factors involved in Alzheimer's disease (AD)?. Neurobiol. Aging 2000, 21:215-224.
28. Kurz A., Reimenschneider M., Drzezga A., Lautenschlager N. The role of biological markers in the early and differential diagnosis of Alzheimer's disease. J. Neural Transm. 2002, 62:127-133.
29. Laske C., Leyhe T., Hoffmann N., Fallgatter A.J., Dietzsch J. Identification of a blood-based biomarker panel for classification of Alzheimer's disease. Int. J. Neuropsychopharmacol. 2011, 14:1147-1155.
30. Lewczuk P., Wiltfang J. Neurochemical dementia diagnostics: state of the art and research perspectives. Proteomics 2008, 8:1292-1301.
31. Llano D.A., Devanarayan V., Simon A.J. The Alzheimer's disease neuroimaging initiative (ADNI). Evaluation of plasma proteomic data for alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2013, 27(3):233-243.
32. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechtcheriakov S., Oberbauer H., Auffinger S., Hinterhölzl J., Hinterhuber H., Humpel C. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2011, 32:539-540.
33. Mattila K.M., Frey H. Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl. Theor. Electrophor. 1995, 4:189-196.
34. McKeel D.W., Price J.L., Miller J.P., Grant E.A., Xiong C., Berg L., Morris J.C. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J. Neuropathol. Exp. Neurol. 2004, 63:1028-1037.
35. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
36. Meier U. A note on the power of Fisher's least significant difference procedure. Pharm. Stat. 2006, 5:253-263.
37. Nilsson K., Gustafson L., Hultberg B. Plasma homocysteine and vascular disease in psychogeriatric patients. Dement. Geriatr. Cogn. Disord. 2006, 21:148-154.
38. Nishiyama K., Tsutamoto T., Tanaka T., Fujii M., Yamamoto T., Yamaji M., Horie M. Plasma NT-proBNP as a more reliable biomarker of endogenous cardiac natriuretic peptides than BNP during carperitide infusion. Int. Heart J. 2009, 50:183-190.
39. Pelech S. Biomarker identification for diagnosis of Alzheimers disease. Expert Opin. Med. Diagn. 2008, 2:577-591.
40. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 2001, 58:1985-1992.
41. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J., Tibshirani R., Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
42. Rocchi A., Orsucci D., Tognoni G., Ceravolo R., Siciliano G. The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. Curr. Alzheimer Res. 2009, 6:224-237.
43. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141:1356-1364.
44. Shaffer J.P. Modified sequentially rejective multiple test procedures. J. Am. Stat. Assoc. 1986, 81:826-831.
45. Soares H.D., Potter W.Z., Pickering E., Kuhn M., Immermann F.W., Shera D.M., Ferm M., Dean R.A., Simon A.J., Swenson F., Siuciak J.A., Kaplow J., Thambisetty M., Zagouras P., Koroshetz W.J., Wan H.I., Trojanowski J.Q., Shaw L.M. For the Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project. Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch. Neurol. 2012, 16:1-8.
46. Sprott R.L. Biomarkers of aging and disease: introduction and definitions. Exp. Gerontol. 2010, 45:2-4.
47. Srisawasdi P., Vanavanan S., Charoenpanichkit C., Kroll M.H. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am. J. Clin. Pathol. 2010, 133(1):14-23.
48. Sunderland T., Hill J.L., Mellow A.M., Lawlor B.A., Gundersheimer J., Newhouse P.A., Grafman J.H. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J. Am. Geriatr. Soc. 1989, 37:725-729.
49. Venugopal J. Cardiac natriuretic peptides-hope or hype?. J. Clin. Pharm. Ther. 2001, 26:15-31.
50. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale - a preliminary-report. J. Psychiatr. Res. 1983, 17:37-49.
51. Zetterberg H., Blennow K., Hanse E. Amyloid beta and APP as biomarkers for Alzheimers disease. Exp. Gerontol. 2010, 45:23-29.
52. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28:202-208.